Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07298915 · ClinicalTrials.gov registry record · Phase 3
The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)
A Phase 3 study, sponsored by University of Virginia.
- Not yet
- Registry status
- Phase 3
- Development phase
- 24
- Enrollment target
NCT07298915 is a Phase 3 study that has not yet begun recruiting, run by University of Virginia. The registered enrollment target is 24 participants.
The verdict
NCT07298915, a Phase 3 study, has not yet begun recruiting, sponsored by University of Virginia.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 24 participants
- Enrollment target
Study Summary
This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity. The main questions it will answer includes: * Does exercise combined with weight loss medication reduce body weight and body fat more than weight loss medication alone * Does exercise combined with weight loss medication improve other risk factors more such as the sugar in the blood, cholesterol, fitness, and quality of life Participants will: * Take a weight loss medication (tirzepatide) monthly under the supervision of their primary care physician * (Exercise group only) Will perform exercise \~3 times a week at the University of Virginia). Walking on a treadmill and resistance training * Visit the study site at the beginning of the study and after the study to evaluate weight, body fat, and other health measures
Interventions
- DRUG Tirzepatide
- BEHAVIORAL Exercise
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2026-08 |
| Est. Completion | 2027-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07298915
The ClinicalTrials.gov registry entry for NCT07298915 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Virginia, which has 449 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT07298915 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07298915 about?
NCT07298915 is a clinical study titled "The Effect of Exercise and Tirzepatide on Weight and Health Outcomes (EXER-MED)". This is clinical trials is to evaluate the effect of exercise with weight loss medication compared to weight loss alone. The study will enroll 24 adults from 30-65 years old with overweight or obesity. The main questions it will answer includes: * Does exercise combined with weight loss medication...
What is the current status of trial NCT07298915?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 24 participants. The study started on 2026-08. Estimated completion is 2027-06.
What interventions are being tested in trial NCT07298915?
The interventions under investigation include: Tirzepatide (DRUG), Exercise (BEHAVIORAL).
Who is sponsoring clinical trial NCT07298915?
This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.